Phase Ib Trial of Pembrolizumab Administered in Combination With or Following Adoptive Cell Therapy- A Multiple Cohort Study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

Trial Profile

Phase Ib Trial of Pembrolizumab Administered in Combination With or Following Adoptive Cell Therapy- A Multiple Cohort Study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2; Tumour infiltrating lymphocytes
  • Indications Brain metastases; Malignant melanoma; Ovarian cancer
  • Focus Adverse reactions
  • Acronyms ACTIVATE
  • Most Recent Events

    • 22 Aug 2017 Status changed from not yet recruiting to recruiting.
    • 22 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top